There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
To study the safety and efficacy of intravitreal injections of ziv-aflibercept (IVI-ZA)
(Zaltrap; Sanofi-Aventis and Regeneron Pharmaceuticals, Tarrytown, NY) during a period
of 48 weeks in patients with diabetic macular edema (DME).